SBI-477

CAS: 781628-99-7

Ref. 3D-GGB62899

Produktinformation

• Name: SBI-477

Beschreibung

SBI-477 is a novel drug candidate that has been shown to have significant efficacy in the treatment of various muscle diseases, including Duchenne muscular dystrophy. It is a fatty acid ester and interacts with the cellular membrane, preventing the uptake of nutrients. SBI-477 has also been shown to have anticancer properties due to its ability to inhibit cancer cell proliferation by blocking insulin receptor signaling. SBI-477 has been shown to block interactions between proteins by targeting an interactome. Additionally, this drug has been shown to be effective in treating acute lymphoblastic leukemia (ALL) in children because it blocks the growth of leukemia cells by interfering with their ability to proliferate and synthesize DNA.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 483.5 g/mol
• Formel: C₂₄H₂₅N₃O₆S
• Reinheit: Min. 95%